Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-94-8,4-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: For compound 1, a 1.0 mL aqueous solution of Ni(ClO4)2¡¤6H2O (0.005mmol) was placed at the bottom of a tube, a mixture of methanol and water (1:2, v/v, 3 mL)was gently layered on the top of the solution, and then a 1.0 mL methanol solutionof Bu4N[Fe(Tp*)(CN)3] (0.005 mmol) and 4-chlorine-2,2?-dibipyridine (0.01 mmol)was carefully added as the top layer. After few weeks, red block crystals were obtained,washed with water and air dried.

14162-94-8, The synthetic route of 14162-94-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Jiao, Yu-Shu; Jiao, Cheng-Qi; Meng, Yin-Shan; Liu, Xue-Ru; Zhao, Liang; Liu, Tao; Inorganic Chemistry Communications; vol. 93; (2018); p. 87 – 91;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

18511-72-3, 4,4-dinitro-2,2-Bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The structural formula of the substituted bipyridine trivalent iron complex 4 described in this embodiment is as follows:Under an argon atmosphere, add anhydrous FeCl3 (64.9 mg, 0.4 mmol) to a 50 mL Schlenk bottle, and dissolve it in 6 mL of absolute ethanol at 60 C;A solution of 4,4′-dinitro-2,2′-bipyridine (98.5 mg, 0.4 mmol) in ethanol (4 mL) was added dropwise to the system. The reaction was carried out at 60 C for 1 hour.A brown complex was precipitated from the system, filtered, washed twice with cold ethanol, concentrated to remove the solvent, and dried under vacuum for 12 h to obtain a tan solid product 4, yield 67%.

18511-72-3, 18511-72-3 4,4-dinitro-2,2-Bipyridine 11519563, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Chinese Academy Of Sciences Tsingtao Biological Energies And Process Institute; Wang Qinggang; Zhu Guangqian; Wang Liang; Zhang Xianhui; Jing Chuyang; (14 pag.)CN110305169; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.

A mixture of H2L (28.6mg, 0.1mmol), Cd(NO3)2¡¤4H2O (30.8mg, 0.1mmol), H2BPDA (24.2mg, 0.1mmol) and NaOH (8.0mg, 0.2mmol) in 10mL of H2O was sealed in a 16mL Teflon lined stainless steel container and heated at 180C for 3d. After the reaction mixture was cooled to room temperature, block crystals of 1 were collected with a yield of 32% by filtration and washed with water several times. Anal. Calc. for C32H22N4O4Cd: C, 60.15; H, 3.47; N, 8.77. Found: C, 60.52; H, 3.52; N, 8.85%. IR (KBr pellet, cm-1, Fig. S8): 1590 (s), 1573 (s), 1547 (s), 1543 (s), 1402 (m), 1126 (m), 1001 (m), 951 (s), 879 (m), 854 (w), 821 (m), 780 (m), 710 (w), 682 (w), 644 (w)., 787-70-2

As the paragraph descriping shows that 787-70-2 is playing an increasingly important role.

Reference£º
Article; Chen, Kai; Kang, Yan-Shang; Luo, Li; Zhao, Yue; Wang, Peng; Liu, Qing; Lu, Yi; Sun, Wei-Yin; Polyhedron; vol. 79; (2014); p. 239 – 249;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.330680-46-1,Trimethyl [2,2′:6′,2”-terpyridine]-4,4′,4”-tricarboxylate,as a common compound, the synthetic route is as follows.

Exemplified dye D-3-1a was synthesized in the same manner as exemplified dye D-1-1a, according to the method shown in the following scheme, except that compound d-1-7 for exemplified dye D-1-1a was changed to compound d-15-1.

330680-46-1, As the paragraph descriping shows that 330680-46-1 is playing an increasingly important role.

Reference£º
Patent; FUJIFILM Corporation; Tani, Yukio; Kobayashi, Katsumi; (63 pag.)US9953768; (2018); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

107-64-2, Dimethyldioctadecylammonium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5. 96 g (0.5 mol) of 3,4-dichloronitrobenzene were reacted with 26 g (0.45 mol) of potassium fluoride and 4 g of distearyldimethylammonium chloride and 4 g of tetraethylene glycol dimethyl ether at 180 C. After 4 h, the conversion was over 50% (GC) with the formation of 3-chloro-4-fluoronitrobenzene.

107-64-2, The synthetic route of 107-64-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Hoechet AG; US5545768; (1996); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13104-56-8, 4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of Ni(NO3)2.6H2O (0.070g, 0.24 mmol), meophtpy(0.078 g, 0.023 mmol) and NaClO4 (0.028 g, 0.023 mmol) inacetonitrile (30 mL) was sonicated for 10min. The resulted clearsolution was left alone until many brown crystals were obtained.Yield: 0.005g, 44.7%. Calcd. For C44H38Cl2N6NiO12 (1): C, 56.61;H, 4.17; N, 10.60%. Found: C, 56.76; H, 4.11; N, 10.67%. IR(KBr,cm1): 3066.82(w), 1600.92(vs), 1519.91(s), 1473.61(s), 1435.04(s), 1367.53(s), 1240.23(s), 1192.01(m), 1087.85(vs), 1024.20(s), 829.39(s), 794.67(vs), 729.09(m), 657.72(m), 621.08(m), 584.43(m), 518.85(m), 418.55(m).

13104-56-8, As the paragraph descriping shows that 13104-56-8 is playing an increasingly important role.

Reference£º
Article; Fu, Wei-Wei; Shen, Jing-Run; Tang, Zi-Qing; Peng, Yong-Qiong; Yi, Qing; Inorganic and Nano-Metal Chemistry; vol. 47; 12; (2017); p. 1664 – 1667;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

294-90-6, 1,4,7,10-Tetraazacyclododecane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of di-te/t-butyl dicarbonate (6.08 g, 27.8 mmol) in anhydrous CH2CI2 (100 ml) was added dropwise to a stirred solution of cyclen (2.00 g, 11.61 mmol) in anhydrous CH2CI2 (300 ml). The reaction mixture was stirred at room temperature, for 18 h. The solvent was removed under reduced pressure to afford a transparent oil. The crude material was purified by column chromatography on silica (gradient elution: CH2CI2 to 5 % CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to yield the title compound 17 as a colourless crystalline solid (3.08 g, 6.51 mmol, 56 %); RF = 0.29 (Silica, CH2CI2 – CH3OH, 9 : 1, v/v); 1H NMR (CDCI3, 500 MHz) delta 1.42 (18H, s, feoc CH3), 1.44 (9H, s, *Boc CH3), 2.81 (4H, br s, cyclen CH2), 3.28 (8H, br s, cyclen CH2), 3.60 (4H, br s, cyclen CH2); 13C NMR (CDCI3, 125 MHz, 1H decoupled 500 MHz) delta 28.9 (6C, ‘Boc CH3), 29.0 (3C, ‘Boc CH3), 46.1 (2C, cyclen CH2), 49.9 (2C, cyclen CH2), 51.2 (4C, cyclen CH2), 79.4 (2C, fex*,)), 79.6 (1C, ^oqq)), 155.8 (2C, feoc C = O), 156.0 (1C, ‘Boc C = O); MS (ES+) m/z 473.3 (100 %, [M + H]+); HRMS (ES+) m/z found 473.3330 [M + H]+ C23H45O6N4 requires 473.3333., 294-90-6

The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CIS BIO INTERNATIONAL; LAMARQUE, Laurent; MONTGOMERY, Craig; PARKER, David; WO2010/84090; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2,56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a flame-dried flask equipped with a magnetic stirring bar and a condenser was added with cinchona alkaloids (1 mmol), toluene (5 mL), and benzyl bromide derivatives (1.2 mmol, 1.2 equiv.). The mixture was heated at 80 8C until a TLC analysis showing that the starting material was completely consumed. Cooled to room temperature and poured onto Et2O (30 mL) with stirring, the resulting suspension was stirred for another 1 h. Then the precipitate was purified by flash chromatography (MeOH/EtOAc = 1/10, V/V). 4.24.3 N-(9-Anthrylmethyl)quinidinium chloride (1c) [26] Yield: 80%; light yellow solid; m.p. 161 C (decomp.) (lit. mp 160 C, decomp.); [alpha]D28 +390.0 (c 0.12, CH3OH); IR (KBr): 3394, 3183, 1621, 1508, 1458, 1473, 1431, 1258, 1362, 1240, 1227, 1029, 922, 864, 744 cm-1; 1H NMR (400 MHz, DMSO-d6): delta = 8.98 (s, 1H), 8.86 (d, J = 4.4 Hz, 1H), 8.79 (d, J = 9.2 Hz, 1H), 8.70 (d, J = 9.2 Hz, 1H), 8.28 (dd, J = 8.2, 3.0 Hz, 2H), 8.05 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 4.4 Hz, 1H), 7.82-7.74 (m, 3H), 7.69-7.64 (m, 3H), 7.53 (dd, J = 7.6, 2.4 Hz, 1H), 6.98 (s, 1H), 6.33 (d, J = 14.4 Hz, 1H), 6.03 (ddd, J = 17.2, 10.2, 7.2 Hz, 1H), 5.88 (d, J = 14.0 Hz, 1H), 5.18 (d, J = 10.4 Hz, 1H), 5.08 (d, J = 17.2 Hz, 1H), 4.46 (t, J = 9.2 Hz, 2H), 4.21 (s, 4H), 3.18 (t, J = 11.2 Hz, 1H), 2.62-2.54 (m, 1H), 2.46-2.35 (m,2H), 1.78 (s, 1H), 1.69 (d, J = 8.4 Hz, 1H), 1.56-1.53 (m, 1H), 1.10-1.04 (m, 1H); 13C NMR (100 MHz, DMSO-d6): delta = 157.9, 147.9, 144.3, 137.9, 133.5, 133.3, 132.5, 131.8, 131.7, 131.6, 130.2, 128.3, 128.0, 126.1, 126.0, 125.3, 125.0, 122.3, 121.0, 119.3, 117.5, 103.2, 67.9, 65.7, 56.5, 56.1, 55.8, 55.6, 37.7, 26.1, 24.2, 21.6.

As the paragraph descriping shows that 56-54-2 is playing an increasingly important role.

Reference£º
Article; Wu, Shaoxiang; Guo, Jiyi; Sohail, Muhammad; Cao, Chengyao; Chen, Fu-Xue; Journal of Fluorine Chemistry; vol. 148; (2013); p. 19 – 29;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1.2 equivalents of HATU were sequentially added to the DMF solution in which the compound 6 was dissolved at 0 C, 2 equivalents of DIPEA and 0.9 equivalents of compound 7, the reaction was naturally warmed to room temperature. After completion of the reaction, it was quenched with water and extracted with ethyl acetate. The organic phase obtained by extraction was dried over anhydrous sodium sulfate and then evaporated. The residue was purified by silica gel column chromatography to give Compound 8., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Beijing University Shenzhen Sheng Yuan; Li Zhicheng; Ye Weijian; Huang Junrong; Liang Zhenhao; (16 pag.)CN108358952; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.

Synthesis of ethyl 2-acetyl-3-(3-bromo-5-fluorophenyl)-4-(4-chlorophenyl)-4-oxobutanoate To a solution of ethyl-2-(3-bromo-5-fluorobenzylidene)-3-oxobutanoate (46.8 g, 148.5 mmol) and 4-chlorobenzaldehyde (21.4 g, 152.2 mmol) in ethanol (240 mL) was added triethylamine (31 mL, 222 mmol). Nitrogen gas was bubbled through the mixture for 5 min and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (6 g, 22 mmol) was then added. The mixture was heated to 70 C. for 2 h under a nitrogen atmosphere. The solvent was removed under vacuum and the residual crude was dissolved in EtOAc (700 mL) and washed with 1 M aqueous HCl (130 mL), water (2*150 mL) and brine (2*20 mL). The organic extract was dried over MgSO4, filtered and concentrated under vacuum to give ethyl 2-acetyl-3-(3-bromo-5-fluorophenyl)-4-(4-chlorophenyl)-4-oxobutanoate as an orange gum (73.1 g) which was used without purification. LCMS (ESI) [M+Na]+=477.0/479.0

4568-71-2, As the paragraph descriping shows that 4568-71-2 is playing an increasingly important role.

Reference£º
Patent; Unity Biotechnology; Beausoleil, Anne-Marie; Hudson, Ryan; (111 pag.)US2019/330250; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI